Full text is available at the source.
Abstract
The effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on various health outcomes in type 2 diabetes are not fully understood compared to other treatments.
- GLP-1RAs may have multisystem effects beyond cardiometabolic outcomes.
- Comparisons are made against active treatments such as sulfonylureas, sodium-glucose cotransporter-2 inhibitors, and dipeptidyl peptidase-4 inhibitors.
- The study focuses on adults diagnosed with type 2 diabetes.
Simplified